Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast CancerJ. Clin. Oncol 2021 Jan 29;[EPub Ahead of Print], A Bardia, V Kaklamani, S Wilks, A Weise, D Richards, W Harb, C Osborne, R Wesolowski, M Karuturi, P Conkling, RG Bagley, Y Wang, MG Conlan, P Kabos
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.